单位：[1]Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China[2]Department of Pulmonary and CriticalCare Medicine, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang, China[3]Department of Pulmonary and Critical CareMedicine, Shenzhen People’s Hospital, Shenzhen, China深圳市康宁医院深圳市人民医院深圳医学信息中心[4]Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital ofZhejiang Chinese Medical University, Hangzhou, China[5]Department of Pulmonary and Critical Care Medicine, Sun Yat-Sen Memorial Hospital,Sun Yat-Sen University, Guangzhou, China中山大学附属第二医院[6]Department of Pulmonary and Critical Care Medicine, Qingdao Municipal Hospital, Qingdao,China[7]Department of Respiratory, The First Affiliated Hospital of Zhejiang University, Hangzhou, China浙江大学医学院附属第一医院[8]Department of Pulmonary and CriticalCare Medicine, Tongji Hospital, Tongji University School of Medicine, Shanghai, China[9]Department of Pulmonary and Critical Care Medicine,Daping Hospital, Amy Military Medical University, Chongqing, China[10]Department of Pulmonary and Critical Care Medicine, Tongji HospitalAffiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属同济医院[11]Department of Pulmonary and CriticalCare Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China[12]Department of Pulmonary andCritical Care Medicine, The Third Xiangya Hospital of Central South University, Changsha, China[13]Department of Pulmonary and Critical CareMedicine, Hangzhou First People’s Hospital, Hangzhou, China[14]Global Medical Affairs, Merck Research Laboratories, MSD China, Shanghai,China
Background: Evidence of treatment against cough variant asthma (CVA) is insufficient for the clinical practice in China. We aimed at evaluating the real-world effectiveness of montelukast (MONT) alone or in combination with low-dose inhaled corticosteroids (ICS) and low-dose ICS plus long-acting beta-2-agonists (LABA) for Chinese CVA patients in a multicentre, prospective, cohort study. Methods: Adult patients diagnosed with CVA defined as chronic cough >8 weeks with a positive bronchial provocation test and normal chest X-ray findings were enrolled at respiratory clinics. Study treatment followed routine clinical practice. The investigators initiated MONT by 10 mg/day alone or in combination with a low-dose ICS +/- LABA and followed up treatment outcomes for 4 weeks. The primary outcome measure was the change in cough score (CS) from baseline. Results: The study enrolled 247 patients (MONT =146, MONT + ICS =38, MONT + ICS/LABA =63). In the primary analysis, the mean change (95% CI) in CS at the end of the study was -1.2 (-1.6, -0.9), -0.9 (-1.5, -0.4), and -1.3 (-1.7, -0.8) in the three groups, respectively. MONT monotherapy had a satisfactory rate of weekly asthma control at the end of the study (83.5%, 95% CI: 75.1%, 89.4%) in the per-protocol analysis. Rates of weekly asthma control were similar in two MONT-based combination regimens (83.9%, 81.4%). Short-acting beta-2-agonist (SABA) user (>= 2 times per week) was 16.8% in the MONT group. Conclusions: The real-world effectiveness of MONT alone or in combination with ICS or ICS and LABA was acceptable for CVA short-term control.
第一作者单位：[1]Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China[*1]Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, National Clinical Research Center for Respiratory Diseases, Beijing 100029, China
通讯作者：
通讯机构：[1]Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China[*1]Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, National Clinical Research Center for Respiratory Diseases, Beijing 100029, China
推荐引用方式(GB/T 7714)：
Jiangtao Lin,Zaiyi Wang,Chen Qiu,et al.A multicenter, prospective, observational study on montelukast monotherapy or montelukast-based combinations treating cough variant asthma[J].JOURNAL of THORACIC DISEASE.2020,12(11):6573-6585.doi:10.21037/jtd-20-1989.
APA：
Jiangtao Lin,Zaiyi Wang,Chen Qiu,Zhen Wang,Shanping Jiang...&Annhua Mao.(2020).A multicenter, prospective, observational study on montelukast monotherapy or montelukast-based combinations treating cough variant asthma.JOURNAL of THORACIC DISEASE,12,(11)
MLA：
Jiangtao Lin,et al."A multicenter, prospective, observational study on montelukast monotherapy or montelukast-based combinations treating cough variant asthma".JOURNAL of THORACIC DISEASE 12..11(2020):6573-6585
